Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia

25 March 2019
– Tildacerfont demonstrates meaningful reduction in key disease biomarkers adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP) and androstenedione (A4)
– Well-tolerated and safe, tildacerfont holds potential as a treatment for patients with congenital adrenal hyperplasia, a rare endocrine disorder

Read More +

 

Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)

08 March 2019
Tildacerfont demonstrates potential to become the first approved therapy for congenital adrenal hyperplasia, a rare endocrine disorder

Read More +

 

Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations

17 July 2018
Moriarty brings 18 years of clinical industry experience to Spruce to advance SPR001, the company’s lead program for congenital adrenal hyperplasia (CAH), through Phase 2 clinical trials and expand into additional indications

Read More +

 

Spruce Biosciences Launches Natural History Study for Congenital Adrenal Hyperplasia in Time for World Rare Disease Day

28 February 2018
Study Aims to Support Patients, Improve Care and Accelerate Research for Rare Disorder by Putting Power in Patients’ Hands

Read More +

Scientist jumps from academia to startup CEO

05 February 2018
At the University of Pennsylvania and in her post-doctoral studies at Stanford University, Alexis Howerton zeroed in on ways the body responds to stress, sleuthing out compounds that could tap into pathways that could be exploited.

Read More +

 

Spruce Biosciences Receives EMA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia

05 January 2017
Spruce Biosciences Receives EMA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia

Read More +

 

Spruce Biosciences Receives FDA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia

04 December 2017
Clinical-stage biotech granted orphan drug designation for the treatment of CAH, a rare endocrine disease

Read More +

 

Spruce Biosciences Appoints Camilla V. Simpson to Board of Directors

13 November 2017
Simpson brings 22 years of industry experience to Spruce, a clinical-stage biotech developing a novel treatment for congenital adrenal hyperplasia, a rare endocrine disease

Read More +

 

Spruce Biosciences Provides Corporate Update on Series A Venture Financing, Leadership Team and Lead Clinical Program

12 October 2017
Clinical-stage, rare endocrine disease Company expands leadership team and advances lead candidate for congenital adrenal hyperplasia

Read More +

 

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. We are leveraging our extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from these diseases. We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.